Roth/MKM analyst Adam Walsh downgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Buy to Neutral with a price target of $41.00.The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE